AlzeCure Pharma AB

Eisai Co., Ltd. has a challenging task ahead in bringing its Biogen, Inc. -partnered amyloid protofibril-clearing antibody Leqembi (lecanemab) to Alzheimer’s patients in a market that is struggling

With the last patient now signed up for a mid-stage trial of its non-opioid drug for peripheral neuropathic pain, Sweden's AlzeCure Pharma AB is hoping to seal a deal soon with a pharma partner. The

AlzeCure Pharma AB of Sweden is developing small-molecule central nervous system drug candidates –that should offer big advantages over biologics, notably better permeability across the blood-brain b